Zachary Silbersher, et al v. Dr. Falk Pharma GmbH, et al
STATE OF NORTH CAROLINA, STATE OF MINNESOTA, STATE OF FLORIDA, STATE OF CONNECTICUT, STATE OF NEW MEXICO, COMMONWEALTH OF MASSACHUSETTS, STATE OF VERMONT, STATE OF NEW HAMPSHIRE, STATE OF NEVADA, COMMONWEALTH OF VIRGINIA, STATE OF COLORADO, STATE OF MARYLAND, STATE OF ILLINOIS, STATE OF WASHINGTON, STATE OF IOWA, STATE OF OKLAHOMA, DISTRICT OF COLUMBIA, STATE OF TENNESSEE, STATE OF MICHIGAN, STATE OF RHODE ISLAND, STATE OF DELAWARE, STATE OF INDIANA, UNITED STATES OF AMERICA, ex rel., STATE OF LOUISIANA, STATE OF TEXAS, STATE OF CALIFORNIA, STATE OF NEW YORK, STATE OF MONTANA, STATE OF HAWAII, STATE OF NEW JERSEY and STATE OF GEORGIA |
VALEANT PHARMACEUTICALS INTERNATIONAL, SALIX PHARMACEUTICALS, LTD., SALIX PHARMACEUTICALS, INC. and VALEANT PHARMACEUTICALS INTERNATIONAL, INC. |
ADAMAS PHARMACEUTICALS, INC. |
DR. FALK PHARMA GMBH |
ZACHARY SILBERSHER, Relator |
20-16256 |
June 26, 2020 |
U.S. Court of Appeals, Ninth Circuit |
Other |
Opinions
We have the following opinions for this case:
Description |
---|
ZACHARY SILBERSHER, ET AL V. DR. FALK PHARMA GMBH, ET AL |
Docket Report
This docket was last retrieved on August 21, 2020. A more recent docket listing may be available from PACER.
Document Text |
---|
Filing 12 Added Attorney(s) Mary Bourke for party(s) Appellant Dr. Falk Pharma GmbH, in case 20-16256 and Appellee Dr. Falk Pharma GmbH, in case 20-16176. [11797798] [20-16176, 20-16256] (QDL) [Entered: 08/21/2020 10:42 AM] |
Filing 11 Filed (ECF) notice of appearance of Mary Bourke (Womble Bond Dickinson (US) LLP, 1313 North Market Street, Ste. 1200, Wilmington, DE 19801) for Appellee Dr. Falk Pharma GmbH in 20-16176, Appellant Dr. Falk Pharma GmbH in 20-16256. Date of service: 08/21/2020. (Party was previously proceeding with counsel.) [11797784] [20-16176, 20-16256] (Bourke, Mary) [Entered: 08/21/2020 10:32 AM] |
Filing 10 Filed (ECF) Appellant Dr. Falk Pharma GmbH in 20-16256, Appellee Dr. Falk Pharma GmbH in 20-16176 Correspondence: Cross-Appellant Dr. Falk Pharma GmbH's Representation Statement. Date of service: 07/17/2020 [11757117] [20-16256, 20-16176] (Mammen, Christian) [Entered: 07/17/2020 02:12 PM] |
Filing 9 MEDIATION ORDER FILED: These cases are RELEASED from the Mediation Program. [11755441] [20-16176, 20-16256] (VS) [Entered: 07/16/2020 01:46 PM] |
Filing 8 Filed (ECF) Appellant Zachary Silbersher in 20-16176, Appellee Zachary Silbersher in 20-16256 Correspondence: Notice of No Transcript Order Pursuant to Circuit Rule 10-3.1(c).. Date of service: 07/15/2020 [11754185] [20-16176, 20-16256] (Herrera, Nicomedes) [Entered: 07/15/2020 02:58 PM] |
Filing 7 COURT UPDATE: Terminated - Adamas Pharmaceuticals, Inc. in 20-16176 and - Adamas Pharmaceuticals, Inc. in 20-16256 [11749189] [20-16176, 20-16256] (TYL) [Entered: 07/10/2020 02:28 PM] |
Filing 6 MEDIATION CONFERENCE SCHEDULED - DIAL-IN AssessmentConference, 07/16/2020, 1:00 p.m., PACIFIC Time. The briefing schedule previously set by the court remains in effect. See order for instructions and details. [11745676] [20-16176, 20-16256] (VS) [Entered: 07/08/2020 10:18 AM] |
Filing 5 The Mediation Questionnaire for this case was filed on 07/03/2020. To submit pertinent confidential information directly to the Circuit Mediators, please use the following # link . Confidential submissions may include any information relevant to mediation of the case and settlement potential, including, but not limited to, settlement history, ongoing or potential settlement discussions, non-litigated party related issues, other pending actions, and timing considerations that may impact mediation efforts.[11741713]. [20-16256] (AD) [Entered: 07/03/2020 06:44 PM] |
Filing 4 Filed (ECF) Appellee Dr. Falk Pharma GmbH in 20-16176, Appellant Dr. Falk Pharma GmbH in 20-16256 Mediation Questionnaire. Date of service: 07/03/2020. [11741675] [20-16176, 20-16256] (Mammen, Christian) [Entered: 07/03/2020 01:57 PM] |
Filing 3 The Mediation Questionnaire for this case was filed on 06/29/2020. To submit pertinent confidential information directly to the Circuit Mediators, please use the following # link . Confidential submissions may include any information relevant to mediation of the case and settlement potential, including, but not limited to, settlement history, ongoing or potential settlement discussions, non-litigated party related issues, other pending actions, and timing considerations that may impact mediation efforts.[11737357]. [20-16256] (AD) [Entered: 06/29/2020 06:44 PM] |
Filing 2 Filed (ECF) Appellant Zachary Silbersher in 20-16176, Appellee Zachary Silbersher in 20-16256 Mediation Questionnaire. Date of service: 06/29/2020. [11737046] [20-16176, 20-16256] (Herrera, Nicomedes) [Entered: 06/29/2020 04:01 PM] |
Filing 1 DOCKETED CAUSE AND ENTERED APPEARANCES OF COUNSEL. SEND MQ: Yes. Setting cross-appeal briefing schedule as follows: Appellant Dr. Falk Pharma GmbH Mediation Questionnaire due on 07/06/2020. First cross appeal brief due 09/21/2020 for Zachary Silbersher. Second brief on cross appeal due 10/21/2020 for Dr. Falk Pharma GmbH, Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Valeant Pharmaceuticals International and Valeant Pharmaceuticals International, Inc.. Third brief on cross appeal due 11/23/2020 for Zachary Silbersher. Optional cross appeal Reply brief for Dr. Falk Pharma GmbH is due within 21 days from service of Third brief on cross appeal. [11734658] [20-16256, 20-16176] (RT) [Entered: 06/26/2020 09:53 AM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.